| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/03/2009 | US20090297478 Methods and Compositions for the Treatment of Lupus Using Clofarabine |
| 12/03/2009 | US20090297477 Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders |
| 12/03/2009 | US20090297476 Novel peptide inhibitors of hepatitis c virus replication |
| 12/03/2009 | US20090297475 Cysteine dioxygenase polymorphisms |
| 12/03/2009 | US20090297474 Method for Detecting or Monitoring Sepsis by Analysing Cytokine mRNA Expression Levels |
| 12/03/2009 | US20090297473 Sulphonylpyrrole Hydrochloride Salts as Histone Deacetylases Inhibitors |
| 12/03/2009 | US20090297472 Hepatitis C Virus Inhibitors |
| 12/03/2009 | US20090297471 Methods For Autologous Stem Cell Transplantation |
| 12/03/2009 | US20090297450 Tumor homing molecules, conjugates derived therefrom, and methods of using same |
| 12/03/2009 | US20090297444 Peptide analogs of alpha-melanocyte stimulating hormone |
| 12/03/2009 | US20090297440 Gene Differentially Expressed in Breast and Bladder Cancer and Encoded Polypeptides |
| 12/03/2009 | US20090297438 Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA) |
| 12/03/2009 | DE102008027133A1 Vollsynthetisches Albumin-Analogon Fully synthetic albumin analogue |
| 12/03/2009 | CA2762314A1 Mechanism of action of primary cell derived biologic |
| 12/03/2009 | CA2726256A1 Variant hhip1 protein and methods and uses thereof |
| 12/03/2009 | CA2726247A1 Method and means for treating viral disease, in particular hiv/aids |
| 12/03/2009 | CA2726231A1 Uses of conglutin-y |
| 12/03/2009 | CA2725596A1 Method of reducing motility in bacteria by overexpression of a gene of oi-1 genomic island |
| 12/03/2009 | CA2725547A1 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| 12/03/2009 | CA2725545A1 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| 12/03/2009 | CA2723580A1 Modulating interstitial pressure and oncolytic viral delivery and distribution |
| 12/03/2009 | CA2721150A1 Indoleamine 2,3-dioxygenase based immunotherapy |
| 12/03/2009 | CA2710040A1 A soluble tumor necrosis factor receptor mutant |
| 12/02/2009 | EP2128623A1 Vascular tumor markers |
| 12/02/2009 | EP2128267A2 Methods of evaluating phosphatase inhibitors |
| 12/02/2009 | EP2128260A2 Modified TGF-beta superfamily proteins |
| 12/02/2009 | EP2128257A2 Mutation of the parkin gene, compositions, methods and uses |
| 12/02/2009 | EP2128246A1 Methods and composition for the production of orthoganal tRNA-Aminoacyl-tRNA synthetase pairs |
| 12/02/2009 | EP2128175A1 Interleukin-10 antibodies |
| 12/02/2009 | EP2127676A2 Treatment of obesity and related disorders |
| 12/02/2009 | EP2127674A1 Hair regrowth promoter |
| 12/02/2009 | EP2127672A1 Inhibitor of herpesvirus infection, method for inhibition of herpesvirus infection, and use thereof |
| 12/02/2009 | EP2127669A1 Use of matrix metalloproteinase-10 (mmp-10) for thrombolytic treatments |
| 12/02/2009 | EP2127668A1 Enzyme composition and use thereof |
| 12/02/2009 | EP2127667A1 Oral disinfectant, food additive comprising the disinfectant |
| 12/02/2009 | EP2127666A1 Method for the treatment or prophylaxis of chronic inflammatory diseases |
| 12/02/2009 | EP2127665A1 Exenatide and dalargin-based medicinal preparation for treating pancreatic diabetes |
| 12/02/2009 | EP2127664A1 Change of the load state of MHC molecules by dipeptides |
| 12/02/2009 | EP2127663A1 Adiponectin production enhancer |
| 12/02/2009 | EP2127662A1 Rankl production inhibitor |
| 12/02/2009 | EP2127642A2 Microemulsions as solid dosage forms for oral administration |
| 12/02/2009 | EP2127540A1 Skin-beautifying agent |
| 12/02/2009 | EP2126127A2 Use of anti-egfr antibodies in treatment of egfr mutant mediated disease |
| 12/02/2009 | EP2126092A2 Fusion proteins binding to growth factors |
| 12/02/2009 | EP2126076A1 Proteins from the webs of nephilengys cruentata, avicularia juruensis and parawixia bistriata spiders |
| 12/02/2009 | EP2126067A2 Treating atherosclerosis |
| 12/02/2009 | EP2126064A2 Mek ligands and polynucleotides encoding mek ligands |
| 12/02/2009 | EP2125884A2 Variants derived from actriib and uses therefor |
| 12/02/2009 | EP2125876A1 Tighter-binding c-peptide inhibitors of hiv-1 entry |
| 12/02/2009 | EP2125874A1 Polypeptide comprising a knottin protein moiety |
| 12/02/2009 | EP2125873A1 Novel therapeutics based on tau/microtubule dynamics |
| 12/02/2009 | EP2125872A1 Basic peptides and their use as combined antibacterial-antifungine agents |
| 12/02/2009 | EP2125871A2 Peptides and their use |
| 12/02/2009 | EP2125870A1 Inhibitors of hepatitis c ns3 protease |
| 12/02/2009 | EP2125113A2 Tertiary amine substituted peptides useful as inhibitors of hcv replication |
| 12/02/2009 | EP2125015A1 Method for the treatment of amyloidoses |
| 12/02/2009 | EP2125004A1 Synergistic therapeutic use of prothrombin complex concentrates with fviii concentrates |
| 12/02/2009 | EP2125003A2 Use of long-acting glp-1 receptor agonists to improve insulin sensitivity and lipid profiles |
| 12/02/2009 | EP2124999A2 Activin-actrii antagonists and uses for increasing red blood cell levels |
| 12/02/2009 | EP2124997A2 Use of il-1 antagonists to treat gout and pseudogout |
| 12/02/2009 | EP2124994A2 Soluble fc gamma r1a for reducing inflammation |
| 12/02/2009 | EP2124992A2 Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
| 12/02/2009 | EP2124991A1 Pharmaceutical compositions and methods for treating erectile dysfunction |
| 12/02/2009 | EP2124990A1 Romidepsin-based treatments for cancer |
| 12/02/2009 | EP2124989A2 Methods of treating infection |
| 12/02/2009 | EP2124988A2 Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease |
| 12/02/2009 | EP2124986A2 Mycobacterium tuberculosis persistance genes |
| 12/02/2009 | EP2124985A2 Methods and compositions for treating neuropathies |
| 12/02/2009 | EP2124962A1 Use of biglycan or enhancers of biglycan activity in the preparation of pharmaceutical compositions |
| 12/02/2009 | EP2124910A2 Targeting of ews-fli1 as anti-tumor therapy |
| 12/02/2009 | EP2124890A2 Use of sucrose to suppress mannitol-induced protein aggregation |
| 12/02/2009 | EP2124889A2 Protein formulations containing sorbitol |
| 12/02/2009 | EP2124883A2 Pharmaceutical formulations and methods for making the same |
| 12/02/2009 | EP2124640A2 Agent for use in the case of fructose intolerance |
| 12/02/2009 | EP2124637A2 Stabilized anthocyanin compositions |
| 12/02/2009 | EP2124548A2 Disintegrin variants and pharmaceutical uses thereof |
| 12/02/2009 | EP1684801B1 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
| 12/02/2009 | EP1633759B1 Cross-linked glycopeptide-cephalosporin antibiotics |
| 12/02/2009 | EP1581249B1 G-csf for use in the treatment of amyotrophic lateral sclerosis |
| 12/02/2009 | EP1487416B1 Drug microparticles |
| 12/02/2009 | EP1436425B1 Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease |
| 12/02/2009 | EP1309726B1 Rna sequence-specific mediators of rna interference |
| 12/02/2009 | CN101595129A Crystal structure of the THSR receptor |
| 12/02/2009 | CN101595122A Long-acting polypeptides and methods of producing and administering same |
| 12/02/2009 | CN101595121A Pyrrolydine derivatives as IAP inhibitors |
| 12/02/2009 | CN101595118A Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and PROP bitter ligands |
| 12/02/2009 | CN101594880A Novel method for treating H.pylori infections |
| 12/02/2009 | CN101594879A Enzyme composition and use thereof |
| 12/02/2009 | CN101594878A Treatment of liver disorders by administration of receptor-associated protein (RAP)-conjugates |
| 12/02/2009 | CN101594877A Concurrent chemotherapy and immunotherapy |
| 12/02/2009 | CN101591649A Methoxypolyethylene glycol-modified arginine deiminase, preparation thereof and use thereof |
| 12/02/2009 | CN101591397A Recombinant expression and application of long-acting thymosin alpha1 |
| 12/02/2009 | CN101591388A Soluble tumor necrosis factor (TNF) receptor mutant |
| 12/02/2009 | CN101591386A Polypeptide capable of inhibiting excitable and toxic damages and use thereof |
| 12/02/2009 | CN101591378A Worm body membrane bound short peptide ZL-4 with specific target and anti-schistosome function and application thereof |
| 12/02/2009 | CN101591377A Aminoacyl-phenylalanyl-tryptophan or derivative, synthetic method and application thereof |
| 12/02/2009 | CN101591376A Oligopeptide with thrombolysis activity, preparation method and application thereof |
| 12/02/2009 | CN101591375A Compound with analgesic activity, preparation method and application thereof |
| 12/02/2009 | CN101591348A Tetrahydrochysene carboline acyl aminoacid benzyl ester, preparation method and application thereof |
| 12/02/2009 | CN101591335A N-(L-aminoacyl)-1, 2, 3, 4-tetrahydrochysene carboline acyl aminoacid benzyl ester, synthetic method and application thereof |